bioMérieux S.A.. (5/31/18). "Press Release: bioMérieux Launches Endozyme II GO, an Innovative Test for the Detection of Endotoxins in Pharmaceutical Microbiology Control". Marcy l’Étoile.

	Organisation	bioMérieux S.A. (Euronext: BIM)
	Group	Mérieux (Group)
	Organisation 2	Hyglos GmbH
	Group	Mérieux (Group)
	Product	Endozyme® II GO endotoxin test
	Product 2	Endonext™ test (product series)
	Index term	Hyglos–Mérieux: investment, 201605 acquisition 100% of Hyglos by bioMérieux for €24m phased over 3 years
	Person	Reynier, Michaël (Mérieux 201805 VP Healthcare Business – Industrial Microbiology Unit at bioMérieux)
	Person 2	Morgeau, Sylvain (Mérieux 201602 Investor Relations at bioMérieux)

bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of ENDOZYME® II GO, a new endotoxin test in the bioMérieux ENDONEXTTM range of recombinant horseshoe crab Factor C (rFC) assays. This new assay resulting from the combined expertise of bioMérieux in microbiology and Hyglos GmbH in endotoxin detection enables endotoxin testing in pharmaceutical grade water, injectable drugs and other pharmaceutical products. This new test allows an easy and fast workflow, and is particularly adapted to raw materials and final product testing.

The animal-free rFC technology, included in the European Pharmacopoeia since 2016, completely eliminates the need to harvest ecologically vulnerable horseshoe crabs endangered in Asia and protected in the United States. Their blood is used in most currently marketed tests for endotoxin detection.

“With its ultra-efficient workflow, the ENDOZYME® II GO assay, offers an alternative to further accelerate the transition to rFC of the endotoxin testing market,” said Michaël Reynier, VP Healthcare Business - Industrial Microbiology Unit at bioMérieux. “This launch is an important achievement from our development teams following the acquisition of Hyglos. Combining our respective expertise, we are strongly committed to increasing the pace of innovation in pharmaceutical endotoxin control.”

Conventional endotoxin testing requires time-consuming preparation of standard dilutions and internal controls. Such manual handling steps may further result in variability and invalid results. The new ENDOZYME® II GO assay uses the GOPLATE™ system, an innovative 96-well microplate pre-filled with required standard curve and positive product control concentrations. It is ready-to-use and enables more than 50% reduction in handling-time in comparison to conventional microplate-based endotoxin tests, as well as high precision in both standard curves and internal controls1 .

bioMérieux presented first evaluation results on ENDOZYME® II GO at the 2018 PDA (Parenteral Drug Association) Annual Meeting, and will progressively roll out for worldwide distribution starting June 2018.

1 Schneider P. and al., 2018

ABOUT BIOMÉRIEUX
PIONEERING DIAGNOSTICS

A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 43 subsidiaries and a large network of distributors. In 2017, revenues reached €2.3 billion, with over 90% of international sales. bioMérieux provides diagnostic solutions (systems, reagents, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market Symbol: BIM - ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP Corporate website: www.biomerieux.com. Investor website: www.biomerieux-finance.com. For more information on our offer for endotoxin detection: www.biomerieux-industry.com/Endotoxin

CONTACTS

Investor Relations

bioMérieux
Sylvain Morgeau
Tel.: +33 (0)4 78 87 22 37
investor.relations@biomerieux.com

Media Relations

bioMérieux
Aurore Sergeant
Tel.: +33 (0)4 78 87 20 53
media@biomerieux.com

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64
lheilbronn@image7.fr
Claire Doligez
Tel.: +33 (0)1 53 70 74 48
cdoligez@image7.fr

Record changed: 2018-07-04